Partner with us to develop the next rare disease therapy
Our drug hunters work in concert with our AI platform to discover and analyse drug-disease-target interactions at scale
In just five years, we’ve discovered and delivered several new treatments towards the clinic. We develop partnerships to license some of these treatments out and to license promising, clinic-ready treatments in.
Our AI is made up of a unique combination of drug-matching, predictive technologies. They empower experts to make:
Our technologies analyse drug structures, pharmacological drug data, drug side effects and associated disease phenotypes to discover novel and hidden connections between targets, drugs and diseases.
Rather than approaching the biology of a rare disease with a predetermined target in mind, our technologies use gene expression data to connect drugs and diseases without prior assumptions.
A greater impact
Our technologies present the connections they discover in the form of a knowledge graph. The results are also prioritised, which helps our pharmacologists speed up the interpretation and validation process.
Our AI leverages its unique combination of algorithms to predict and de-risk novel connections in biomedical data, and move the most promising ones towards the clinic.
We’re a next-generation team of drug hunters, AI engineers and bioinformaticians, all working together to accelerate the discovery of new treatments for rare diseases.